ロード中...
Learning from the Recently Completed Oral Glycoprotein IIb/IIIa Receptor Antagonist Trials
Although parenteral therapy with glycoprotein (GP) IIb/IIIa inhibitors has resulted in a reduced risk of death or myocardial infarction in patients with acute coronary syndromes and in patients undergoing percutaneous coronary intervention, the benefit is achieved only during the infusion period. Or...
保存先:
| 出版年: | Clin Cardiol |
|---|---|
| 第一著者: | |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Wiley Periodicals, Inc.
2009
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6654967/ https://ncbi.nlm.nih.gov/pubmed/11129681 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/clc.4960231105 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|